chitosan has been researched along with Diabetic Retinopathy in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alhajlah, S; AlOmeir, O; Alrouji, M; Chellappan, DK; Chitranshi, N; Dua, K; Gulati, M; Gupta, G; Gupta, VK; Khursheed, R; Kumar, A; Kumar, B; Loebenberg, R; Morris, A; Parveen, SR; Saini, S; Sharma, DS; Singh, SK; Vishwas, S; Wadhwa, S; Zacconi, F | 1 |
| Aqil, M; Pandit, J; Sultana, Y | 1 |
| Ji, Y; Lu, Y; Mo, X; Qian, D; Rong, X; Yang, J; Zhu, X | 1 |
| Chen, L; Deng, DY; Huang, P; Long, L; Luo, J; Tan, J; Wang, J; Yang, L; Zhang, LM; Zhou, W; Zhu, B | 1 |
4 other study(ies) available for chitosan and Diabetic Retinopathy
| Article | Year |
|---|---|
Chitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: A new dimension to an anticancer drug.
Topics: Animals; Antineoplastic Agents; Chitosan; Diabetes Mellitus; Diabetic Retinopathy; Drug Carriers; Drug Liberation; Fluorouracil; Lipids; Nanostructures; Particle Size; Rats | 2023 |
Chitosan coated nanoparticles for efficient delivery of bevacizumab in the posterior ocular tissues via subconjunctival administration.
Topics: Animals; Bevacizumab; Chitosan; Delayed-Action Preparations; Diabetic Retinopathy; Drug Carriers; Drug Liberation; Female; Glycolates; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Posterior Eye Segment; Rats; Retina; Streptozocin | 2021 |
Neuroprotective effect of insulin-loaded chitosan nanoparticles/PLGA-PEG-PLGA hydrogel on diabetic retinopathy in rats.
Topics: Animals; Apoptosis; Chitosan; Diabetic Retinopathy; Electroretinography; Glial Fibrillary Acidic Protein; Hydrogels; Insulin; Male; Nanoparticles; Neuroprotective Agents; Occludin; Polyethylene Glycols; Polyglactin 910; Rats, Sprague-Dawley; Retina; Vascular Endothelial Growth Factor A | 2019 |
Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.
Topics: Administration, Oral; Animals; Apigenin; Biological Availability; Caco-2 Cells; Chitosan; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Drug Carriers; Drugs, Chinese Herbal; Erigeron; Glucuronates; Humans; Male; Nanoparticles; Rats, Sprague-Dawley; Retinal Vessels; Vascular Endothelial Growth Factor A; Vitamin B 12; Zebrafish | 2017 |